09:45 AM EDT, 08/14/2025 (MT Newswires) -- Trinity Biotech ( TRIB ) shares were up sharply Thursday morning after the company said it received approval from the New York State Department of Health to start providing its PreClara Ratio biomarker test for the assessment of preeclampsia risk.

Trinity said it plans to roll out the service in Q3.

The company said the PreClara Ratio test is designed to help assess the likelihood of progression to severe preeclampsia.

Price: 1.85, Change: +0.84, Percent Change: +83.21